CCL3 and neoplasm: For example, in the B16.F10 murine melanoma model, TLR2 agonists stimulate the release of MC-derived interleukin-6 and CCL3, which directly inhibit tumor growth and indirectly facilitate the recruitment of natural killer cells (NKs) [157].